www.fdanews.com/articles/174848-vical-garners-orphan-status-for-experimental-antifungal
Vical Garners Orphan Status for Experimental Antifungal
January 12, 2016
San Diego-based Vical’s experimental antifungal VL-2397 has received an orphan drug designation from the FDA.
Designed to fight invasive aspergillosis, the candidate is headed for early clinical trials in the first half of this year. It previously had snagged the FDA’s qualified infectious disease product classification.
The biotech, which bought VL-2397 from Astellas in March 2015, says the candidate works more quickly than currently available products.